CDK2 and breast cancer: Second, acquired resistance to CDK4/6 inhibition in luminal breast cancers may be driven by cyclin E/CDK2 activity (facilitating S-phase entry despite CDK4/6 blockade), providing rationale for studying the inhibition of CDK2 in these tumors as well (12–14).